Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival

Prognostic implication of serum cytokeratin 19 fragments (CYFRA 21-1) was explored in 60 advanced NSCLC patients, whereas in 45 patients assessable for serological response a ⩾35% CYFRA 21-1 decline after two chemotherapy cycles was strongly associated with non-progression (NP), defined as a sum of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nisman, B, Biran, H, Heching, N, Barak, V, Ramu, N, Nemirovsky, I, Peretz, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359680/
https://www.ncbi.nlm.nih.gov/pubmed/18087272
http://dx.doi.org/10.1038/sj.bjc.6604157
_version_ 1782152890879574016
author Nisman, B
Biran, H
Heching, N
Barak, V
Ramu, N
Nemirovsky, I
Peretz, T
author_facet Nisman, B
Biran, H
Heching, N
Barak, V
Ramu, N
Nemirovsky, I
Peretz, T
author_sort Nisman, B
collection PubMed
description Prognostic implication of serum cytokeratin 19 fragments (CYFRA 21-1) was explored in 60 advanced NSCLC patients, whereas in 45 patients assessable for serological response a ⩾35% CYFRA 21-1 decline after two chemotherapy cycles was strongly associated with non-progression (NP), defined as a sum of objective response (OR)+stable disease (P<0.0001) and survival (P=0.0002). Association of OR with survival was not significant. In multivariate survival analysis, ⩾35% marker decline and radiological NP status were found as major determinants of prolonged survival with RR: 0.37 (P=0.01) and 0.63 (P=0.01), respectively. In advanced NSCLC patients, NP reflects therapeutic efficacy better than traditional OR. CYFRA 21-1 ⩾35% decline seems to be a reliable surrogate marker of treatment efficacy in terms of survival.
format Text
id pubmed-2359680
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23596802009-09-10 Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival Nisman, B Biran, H Heching, N Barak, V Ramu, N Nemirovsky, I Peretz, T Br J Cancer Clinical Study Prognostic implication of serum cytokeratin 19 fragments (CYFRA 21-1) was explored in 60 advanced NSCLC patients, whereas in 45 patients assessable for serological response a ⩾35% CYFRA 21-1 decline after two chemotherapy cycles was strongly associated with non-progression (NP), defined as a sum of objective response (OR)+stable disease (P<0.0001) and survival (P=0.0002). Association of OR with survival was not significant. In multivariate survival analysis, ⩾35% marker decline and radiological NP status were found as major determinants of prolonged survival with RR: 0.37 (P=0.01) and 0.63 (P=0.01), respectively. In advanced NSCLC patients, NP reflects therapeutic efficacy better than traditional OR. CYFRA 21-1 ⩾35% decline seems to be a reliable surrogate marker of treatment efficacy in terms of survival. Nature Publishing Group 2008-01-15 2007-12-18 /pmc/articles/PMC2359680/ /pubmed/18087272 http://dx.doi.org/10.1038/sj.bjc.6604157 Text en Copyright © 2008 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Nisman, B
Biran, H
Heching, N
Barak, V
Ramu, N
Nemirovsky, I
Peretz, T
Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival
title Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival
title_full Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival
title_fullStr Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival
title_full_unstemmed Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival
title_short Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival
title_sort prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359680/
https://www.ncbi.nlm.nih.gov/pubmed/18087272
http://dx.doi.org/10.1038/sj.bjc.6604157
work_keys_str_mv AT nismanb prognosticroleofserumcytokeratin19fragmentsinadvancednonsmallcelllungcancerassociationofmarkerchangesaftertwochemotherapycycleswithdifferentmeasuresofclinicalresponseandsurvival
AT biranh prognosticroleofserumcytokeratin19fragmentsinadvancednonsmallcelllungcancerassociationofmarkerchangesaftertwochemotherapycycleswithdifferentmeasuresofclinicalresponseandsurvival
AT hechingn prognosticroleofserumcytokeratin19fragmentsinadvancednonsmallcelllungcancerassociationofmarkerchangesaftertwochemotherapycycleswithdifferentmeasuresofclinicalresponseandsurvival
AT barakv prognosticroleofserumcytokeratin19fragmentsinadvancednonsmallcelllungcancerassociationofmarkerchangesaftertwochemotherapycycleswithdifferentmeasuresofclinicalresponseandsurvival
AT ramun prognosticroleofserumcytokeratin19fragmentsinadvancednonsmallcelllungcancerassociationofmarkerchangesaftertwochemotherapycycleswithdifferentmeasuresofclinicalresponseandsurvival
AT nemirovskyi prognosticroleofserumcytokeratin19fragmentsinadvancednonsmallcelllungcancerassociationofmarkerchangesaftertwochemotherapycycleswithdifferentmeasuresofclinicalresponseandsurvival
AT peretzt prognosticroleofserumcytokeratin19fragmentsinadvancednonsmallcelllungcancerassociationofmarkerchangesaftertwochemotherapycycleswithdifferentmeasuresofclinicalresponseandsurvival

Ejemplares similares